Amsparity 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IAIN/0007 
A.5.a - Administrative change - Change in the name 
12/12/2023 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
PSUSA/10783
Periodic Safety Update EU Single assessment - 
31/08/2023 
n/a 
PRAC Recommendation - maintenance 
/202212 
adalimumab 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
IA/0005 
B.II.e.7.b - Change in supplier of packaging 
06/07/2022 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IB/0004 
C.I.11.z - Introduction of, or change(s) to, the 
23/09/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0003 
C.I.z - Changes (Safety/Efficacy) of Human and 
12/07/2021 
08/07/2022 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0002 
C.I.2.a - Change in the SPC, Labelling or PL of a 
26/04/2021 
19/05/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0001 
C.I.z - Changes (Safety/Efficacy) of Human and 
23/10/2020 
19/05/2021 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
